Holmdel, NJ, United States of America

Shalini Cornelio

USPTO Granted Patents = 2 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2021-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shalini Cornelio: Innovator in Kidney Injury Treatment

Introduction

Shalini Cornelio is a notable inventor based in Holmdel, NJ (US). She has made significant contributions to the field of medicine, particularly in the prevention and treatment of contrast-induced acute kidney injury. With a total of 2 patents, her work is paving the way for innovative therapeutic methods.

Latest Patents

Cornelio's latest patents focus on methods for preventing, reducing, and treating contrast-induced acute kidney injury. These methods include administering an inhibitor of fatty acid oxidation to patients in need. Additionally, her patents involve the use of trimetazidine or its pharmaceutically acceptable salts for the same purpose. Other methods outlined in her patents include the administration of various compounds such as etomoxir, oxfenicine, perhexiline, mildronate, or ranolazine, which are also aimed at preventing and treating this condition.

Career Highlights

Shalini Cornelio is currently associated with Saghmos Therapeutics, Inc., where she continues to develop her innovative ideas. Her work is characterized by a strong focus on improving patient outcomes through advanced medical treatments.

Collaborations

Cornelio collaborates with Anna Kazanchyan, who is also a key figure in her research endeavors. Together, they work towards enhancing the effectiveness of treatments for kidney injuries.

Conclusion

Shalini Cornelio's contributions to medical science, particularly in the area of kidney injury treatment, highlight her role as an influential inventor. Her innovative patents and ongoing work at Saghmos Therapeutics, Inc. demonstrate her commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…